Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director Alex Slanix Paul reported receiving two grants of stock options. One award covers 11,000 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036, that vest in full on May 20, 2027 subject to continued Board service. A second award covers 5,500 options at the same exercise price and expiration date, with 25% vesting immediately on grant and the remaining options vesting ratably over thirty-six months, also contingent on continued service.

Insights

Equity compensation analyst

Director received routine option grants as equity compensation, not open-market trades.

Director Alex Slanix Paul was granted options over 11,000 and 5,500 Common Shares at an exercise price of $10.77, expiring on May 20, 2036. These awards are classified as grant/award acquisitions, not market purchases or sales.

The footnotes show standard vesting terms: one grant vests fully on May 20, 2027, while the other vests 25% immediately and the balance monthly over thirty-six months, all conditioned on continued Board service. This pattern is typical for director compensation and does not represent a discretionary buy or sell signal.

The filing also shows no remaining derivative positions beyond these awards in the derivative summary, indicating only the newly granted options are visible here. Future company disclosures may update Paul’s total equity exposure as additional awards are granted or existing options vest or are exercised.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Alex Slanix Paul

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	5,500	$0.00	--
Grant/Award	Option (right to buy)	11,000	$0.00	--

Holdings After Transaction: Option (right to buy) — 5,500 shares (Direct, null)

Footnotes (1)

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

Key Figures

Option grant size 1: 11,000 options Option grant size 2: 5,500 options Exercise price: $10.77 per share +3 more

6 metrics

Option grant size 1 11,000 options Grant of Option (right to buy) on Common Shares

Option grant size 2 5,500 options Second Option (right to buy) grant on same date

Exercise price $10.77 per share Conversion or exercise price for both option grants

Expiration date May 20, 2036 Option expiration date for both grants

Vesting date (full-vest grant) May 20, 2027 One option grant vests in full on this date

Immediate vesting portion 25% of 5,500 options Portion that vested upon grant for second award

Key Terms

Option (right to buy), grant/award acquisition, conversion or exercise price, vest, +1 more

5 terms

Option (right to buy) financial

"security_title: Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 10.7700"

vest financial

"shares subject to this option shall vest in full on May 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

ratably over thirty-six months financial

"remaining shares vesting ratably over thirty-six months"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alex Slanix Paul

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		5,500		(1)	05/20/2036	Common Shares	5,500	$0	5,500	D
Option (right to buy)	$10.77	05/20/2026		A		11,000		(2)	05/20/2036	Common Shares	11,000	$0	11,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

	/s/ Max Milbury, Attorney in Fact for Slanix Paul Alex	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ProMIS Neurosciences (PMN) director Alex Slanix Paul report in this Form 4?

Alex Slanix Paul reported receiving two stock option grants as director compensation. The awards cover 11,000 and 5,500 options to buy ProMIS Neurosciences Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036.

How many ProMIS Neurosciences (PMN) options were granted to the director and at what price?

The director was granted 11,000 options and 5,500 options to purchase Common Shares. Each option has an exercise price of $10.77 per share and an expiration date of May 20, 2036, according to the Form 4 insider filing.

What are the vesting terms of Alex Slanix Paul’s ProMIS Neurosciences (PMN) option awards?

One option grant vests in full on May 20, 2027, subject to continued Board service. The other grant vests 25% immediately upon grant, with the remaining shares vesting ratably over thirty-six months, also conditioned on continued service on the Board.

Are Alex Slanix Paul’s ProMIS Neurosciences (PMN) transactions open-market buys or sales?

The reported transactions are option grant awards, not open-market trades. They are coded as grant, award, or other acquisition (code A), reflecting routine equity compensation for Board service rather than discretionary buying or selling of existing ProMIS Neurosciences shares.

What is the expiration date of the ProMIS Neurosciences (PMN) options granted to the director?

Both option grants to the director share the same expiration date of May 20, 2036. After this date, any unexercised options will lapse, so the director must exercise vested options on or before that expiration to acquire the underlying Common Shares.

Does the Form 4 for ProMIS Neurosciences (PMN) show any option exercises by the director?

No option exercises are reported in this Form 4. The transactions are classified as derivative grants (code A), and the transaction summary shows zero exercise transactions, indicating no options were converted into Common Shares in this particular filing.